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Abstract: The use of psychotropic medication in children is increasing worldwide. Children with 
developmental disabilities seem to be prescribed these medications at a higher rate compared to 
their non-disabled peers. Little is known about prescribing in non-Western, middle-income studies. 
In Iran, the file records of 1133 children, aged 2 to 17 years, assessed as having autism spectrum 
disorder (ASD) or an intellectual disability (ID) in Tehran City and Province from 2005 to 2019 were 
collated, and information from parental reports of medications was extracted. Upwards of 80% of 
children with ASD and 56% of those with ID were prescribed a psychotropic medication with 
around one quarter in each group taking two or more medications. The rates were higher among 
male children showing difficult-to-manage behaviors such as hyperactivity, but less so for children 
of fathers with higher levels of education. The lack of alternative management strategies may be a 
significant driver for the use of psychotropic medications in Iran and other Low and Middle Income 
countries, despite their known side effects, and their failure to address the developmental needs of 
the children. Rather, multi-disciplinary, behavioral, therapeutic, and educational interventions are 
required, but these are not available widely in Iran, although a start has been made. 
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1. Introduction 
International concern has been expressed about the overuse of psychotropic 
medication in children and particularly those with conditions such as autism spectrum 
disorder (ASD) and intellectual disabilities (ID) [1]. A meta-analysis of 13 studies [2] of 
ASD youth aged 8–11 years (totaling 96,688 participants) reported that 17.5% (95% 
confidence interval, 13.7% to 22.1%) received antipsychotics with a suggestion that this 
proportion had increased in recent years. A more recent national study in the US [3] 
involving nearly 8000 youth with ASD individually matched to 10 peers without ASD (n 
= approximately 80,000) found that those with ASD were over 11 times more likely to be 
prescribed psychotropic medication. Their use was fairly rare among pre-school children 
with ASD (5.7%) but far higher among school-aged children (39.0%) and adolescents 
(59.1%). 
Risperidone was the most commonly prescribed medication across most studies and 
is only one of two antipsychotic medications—the other is aripiprazole—approved by the 
US Food and Drug Administration for use in children [4]. The other commonly prescribed 
drugs include fluoxetine, methylphenidate (Ritalin), clonidine, and haloperidol [2–5]. 
Moreover, sizeable proportions of persons with ASD were prescribed two or more 
medications: a median of 23% in the studies in a further systematic review with children 
and adults [6]. Multiple usage of psychotropic drugs is more common in older youth and 
adults. 
Citation: McConkey, R.; Samadi, 
S.A.; Mahmoodizadeh, A.; Taggart, 
L. The Use of Psychotropic 
Medication in Iranian Children with 
Developmental Disabilities. Int. J. 
Environ. Res. Public Health 2021, 18, 
4120. https://doi.org/10.3390/ 
ijerph18084120 
Academic Editor: Benito Arias 
Received: 10 March 2021 
Accepted: 10 April 2021 
Published: 13 April 2021 
Publisher’s Note: MDPI stays 
neutral with regard to jurisdictional 
claims in published maps and 
institutional affiliations. 
 
Copyright: © 2021 by the authors. 
Licensee MDPI, Basel, Switzerland. 
This article is an open access article 
distributed under the terms and 
conditions of the Creative Commons 
Attribution (CC BY) license 
(http://creativecommons.org/licenses
/by/4.0/). 
Int. J. Environ. Res. Public Health 2021, 18, 4120 2 of 9 
 
There is limited evidence that medications influence the core symptoms of ASD, such 
as social interaction and communication, and the presence of restricted behaviors, 
interests, and activities [7]. Rather, the medications are aimed at addressing associated 
behavioral symptoms, such as irritability, tantrums, aggression, self-harm, hyperactivity, 
and impulsivity. Recent reviews of well-conducted randomized control trials contrasting 
risperidone with placebos report improvements in irritability and tantrums with some 
reduction in aggressive episodes and self-injurious behaviors [7,8]. Likewise, 
methylphenidate (Ritalin) has been well studied with improvements noted in 
hyperactivity and impulsivity across multiple studies, but no benefits were found for 
other common ASD-related behaviors, including stereotypies, repetitive behaviors, and 
oppositional behaviors [8]. However, there have been limited trials of other anti-psychotic 
medications in children and adolescents. 
However, the gains from using psychotropic drugs have to be measured against the 
significant side effects of taking such medications. Rapid weight gain, increased appetite, 
fatigue, and anxiety are common with risperidone treatment of ASD. Similarly, 
methylphenidate has also been associated with significant adverse side effects, including 
decreased appetite, increased irritability, and social withdrawal [8,9]. Other psychotropic 
medications have not been licensed for use in children, so possible deleterious effects have 
not been recorded. Hence, there is a need for careful monitoring of children by 
experienced clinicians, such as child and adult psychiatrists and pediatricians, especially 
when medications are used ‘off-label’ over longer time periods [5,10]. 
The use of psychotropic medications in children who have intellectual disabilities has 
received much less attention in the literature with a focus mostly on adults. However, 
concerns have been expressed about the overuse of these drugs in children as a means of 
managing their challenging behaviors as most antipsychotic drugs are only licensed for 
short-term use in children of up to six weeks [11]. Although the evidence base for their 
use is weak, a systematic review found that risperidone and aripiprazole reduced 
challenging behavior among children with intellectual disabilities in the short term but 
with significant side effects as noted previously [12]. Little is known about the possible 
effectiveness of these drugs in comparison with their use in children who do not have an 
intellectual disability or about the interactions with other medications prescribed for 
children with intellectual disabilities [11]. 
To date, much of the research into medications and children with developmental 
disabilities such as ASD and intellectual disabilities has been undertaken in affluent 
Western countries with marked differences found between medication usage in the US 
and European countries [13], but with few reports of studies in low- and middle-income 
countries. In these countries—such as Iran—services for children with ASD and with 
intellectual disabilities are much less developed with few trained pediatricians, child 
psychiatrists, clinical psychologists, and other specialists available to provide guidance 
and advice to parents on how to manage their child with developmental disabilities [14]. 
Instead, families often rely on general physicians for diagnosing their child and helping 
them to manage their behaviors. A small-scale study undertaken in Tehran city in 2010–
2011 with 354 children with ASD aged 7 to 14 years found that 80% reported taking at 
least one psychotropic medication with few differences regarding age or gender [15]. 
The present study aimed to examine more recent data on psychotropic medications 
with a younger and larger cohort of Iranian children with ASD and also those with 
intellectual disabilities as they rarely feature in the international literature. 
1.1. Aims 
The aims of this study were as follows: 
1. To document the use of psychotropic medication in Iranian children who had a 
diagnosis of ASD or intellectual disability. 
2. To identify the predictors associated with the use of psychotropic medication. 
Int. J. Environ. Res. Public Health 2021, 18, 4120 3 of 9 
 
3. To compare children receiving polypharmacy treatment against those using a single 
psychotropic medication. 
1.2. Country Context 
Iran has an estimated population of 85 million people, 75% of whom live in urban 
areas with the capital Tehran having over 7 million. Around one quarter are aged under 
15 years, but this proportion is declining as the birth rate in 2020 for women was 1.7 
children [16]. The World Bank classifies Iran as having an upper-middle-income economy, 
but in recent years unemployment and poverty levels have risen [17]. 
Nearly all children (97%) are enrolled in primary education. A national screening 
program is undertaken for all children prior to admission to the first grade of elementary 
schools [18]. This mandatory program started in 1993 and is held at central locations 
around the country. Different professionals in the field of child development, including 
general physicians, nurses, and other health professionals, assess the children’s physical 
health, height, weight, vision, and hearing as well as administering a dental check. A 
trained educational evaluator examines child readiness for academic learning. Additional 
information is obtained from parental reports, including the child’s communication skills 
and behaviors, and, of particular relevance to this study, details of medication prescribed 
for the child are collected. Parents are requested to bring written prescriptions signed by 
a medical professional or general physician. 
The process aims to help schools to provide for the children’s health and educational 
needs and to identify those with special educational needs. Those who are suspected of 
having developmental disabilities are referred to the Iranian Special Education 
Organization (ISEO) for diagnostic assessment, which is undertaken by trained 
psychologists and educators. The diagnosis of children with ASD is based on the Autism 
Diagnostic Interview—Revised (ADI-R) [19], and intellectual disabilities are assessed 
using the Wechsler Intelligence Scale for Children—Fifth Edition Integrated (WISC-IV) 
[20]. Both of these assessment tools have been translated and validated for use with 
Iranian children. 
Young children with more severe intellectual disabilities and/or ASD are referred to 
centers run by the Iranian Social Welfare Organization for assessment and day care as 
they are deemed ineligible to attend schools. 
2. Materials and Methods 
2.1. Participants and Procedure 
For the purposes of this study, the file records of children assessed as having ASD or 
ID in Tehran Province and the City of Tehran from 2005 to 2019 were collated. The 
rationale was two-fold. Families were more likely to have access to medical and other 
professionals, and also the recordkeeping was judged better in this province as the ISEO 
professionals had more opportunity for in-service training and supervision from senior 
staff. Although most of the children were currently residents of this province, subjects 
included children from families who had moved from other provinces and some had 
travelled to Tehran for the assessment. 
In all, 1133 children with a diagnosis of ASD or intellectual disability were identified. 
Children with ASD were further divided using DSM-5 guidance and based on ADI-R 
assessments [21] into those with ASD Level 1 (mild impairments) and ASD Levels 2 and 
3 (more severe impairments). The information contained in the children’s screening and 
assessment files was transferred to an Excel spreadsheet and cross-checked for accuracy. 
There were no missing data on the variables included in the analyses. 
Table 1 summarizes the characteristics of the children and families involved in the 
study. 
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Table 1. The demographic characteristics of the sample (n = 1133). 
Children Number % 
Sex  
Male 896 79.1 
Female 237 20.9 
Age Groups 
2–5 years 296 26.1 
6–7 years 471 41.6 
8–17 years 366 32.3 
Developmental disability 
ASD Level 1 702 62.0 
ASD Levels 2 and 3 90 7.9 
ID 341 30.1 
Age of onset 
<12 months 239 21.2 
12–23 months 175 15.5 
24–35 months 371 32.8 
36–47 months 226 20.0 
48+ months 128 11.3 
Siblings  
Only child 448 39.5 
One sibling 478 42.2 
Two or more 207 18.3 
Family Number % 
Mother’s age 
Under 35 yrs 517 45.6 
35+ years 616 54.4 
Father’s age 
Under 40 yrs 546 48.2 
40+ yrs 587 51.8 
Mother’s Education 
Elementary 130 11.5 
Middle school 184 16.2 
High school 425 37.5 
University  394 34.8 
Father’s Education 
Elementary 170 15.0 
Middle school 136 12.0 
High school 372 32.8 
University  455 40.2 
ASD: Autism Spectrum Disorder: ID—Intellectual Disability 
2.2. Data Analysis 
The Statistical Package for Social Science (SPSS vers. 25: IBM, UK) was used to 
summarize the demographic characteristics of the children and families along with 
various medications they were prescribed at the time of assessment. Bivariate analyses 
based on chi-square tests (p < 0.01) were used to identify significant predictors of 
psychotropic medications along with a test of effect size: Cramer’s V. Discriminant 
analyses were used to identify the predictors that best discriminated children who 
received any psychotropic medication from those who had no medications prescribed and 
also those children who received two or more psychotropic medications (polypharmacy) 
from those on a single psychotropic medication. 
3. Results 
3.1. Medication 
Table 2 summarizes the medications prescribed for the children grouped by the 
nature of their developmental disabilities. The differences were statistically significant 
with a medium to large effect size (chi sq = 85.85: df 6: p < 0.001: Cramer’s V = 0.195). The 
pattern of medication usage was similar for the children at all levels of ASD. However, 
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many more children with ID did not receive any medication and fewer received a single 
psychotropic medication. The percentages receiving two or more psychotropics (Poly) 
and anti-convulsants were similar across all groups. 
Table 2. The number and percentage of children receiving medication. 
Medication 
ASD Levels 2 and 3 
(n = 90) 
ASD Level 1 
(n = 702) 
ID 
(n = 341) 
None  19 (21.1%) 109 (15.5%) 138 (40.5%) 
Single psychotropic 45 (50.0%) 344 (49.0%) 99 (29.0%) 
Poly psychotropics 21 (23.3%) 194 (27.6%) 80 (23.5%) 
Anti-convulsant 5 (5.6%) 55 (7.8%) 24 (7.0%) 
The most commonly prescribed psychotropic medications were risperidone and 
Ritalin, but others included memantine, fluoxetine (Prozac), clonidine, haloperidol, and 
paliperidone. The anti-convulsant medications included lamotrigine, sodium valproate, 
and carbamazepine. 
In all, 38 children (3.4%) were reported to experience seizures of whom 10 (26.3%) 
were prescribed anti-convulsants with 25 (65.8%) taking psychotropic medication and 3 
(7.9%) having no medication. 
3.2. Predictors of Psychotropic Medication 
Bivariate tests were undertaken based on the use of medication and other possible 
predictors, such as child and family characteristics as shown in Table 1, along with 
parental reports of the child’s behaviors. Of the latter, the most commonly reported were 
wandering (n = 318:28.1%), hyperactivity (n = 295:26.0%), aimless pacing (n = 201:17.7%), 
lack of understanding of danger (n = 93:8.2%), sleep problems (n = 91:8.0%), and aggressive 
behavior (n = 49:4.3%). However, 548 (48.4%) children showed none of these problems, 
221 (19.5%) showed one behavior, 181 (16.0%) two behaviors, and 183 (16.2%) three or 
more behaviors. 
A series of discriminant analyses were undertaken to compare the children who were 
prescribed psychotropic medications (n = 781) and no medications (n = 266). First, the 
behavior variables that had a significant relationship with the use of psychotropic 
medication were entered into each analysis. The behaviors that best discriminated the use 
of psychotropic medications were hyperactivity, aimless walking, and wandering. 
Likewise, the child and family characteristics associated with psychotropic 
medications were included in a further discriminant analysis. The best discriminating 
variables were the nature of the child’s disability, father’s level of education, the child’s 
age, and gender. 
A third discriminant analysis combined the predictors noted above. The resulting 
model was significant and consisted of one function (canonical correlation 0.324; Wilk’s 
Lambda 0.895: chi sq 115.6: df 7; p < 0.001). Table 3 summarizes the structure matrix of the 
variables that contributed significantly to the discriminant function. 
Table 3. The structure matrix of variables that best discriminated between children receiving psychotropic medication 
and the percentages within the subgroupings of the predictor variable. 
Variables Loading % Psychotropic Medication 
Type of disability 0.684 ASD Levels 2 and 3 (77.6%), ASD Level 1 (83.2%), ID (56.5%) 
Father’s education  0.440 
Elementary (82.8%), middle school (85.8%), high school (76.8%), university 
(66.9%) 
Hyperactivity 0.434 Hyperactivity (85.8%), no hyperactivity (71.0%)  
Aimless pacing  0.420 Paces (88.8%), no pacing (71.9%)  
Age group of child  0.340 2–5 yrs (61.1%), 6–7 yrs (82.9%), 8+ yrs (75.4%)  
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Gender  0.334 Male (77.2%), female (65.0%) 
Wandering 0.272 Wanders (81.1%), no wondering (72.1%) 
The values shown in the table are similar to the variable loadings in a factor analysis. 
The combination of all these variables contributes to the likelihood that children will have 
psychotropic medication prescribed. 
Children with ASD at all levels were more likely than those with intellectual 
disabilities to receive a psychotropic medication. A father’s level of education was the next 
best discriminator with children of fathers with elementary- or middle-school education 
more likely to have psychotropic medication prescribed. Children’s behaviors were also 
associated with the psychotropic prescriptions, along with males and children aged six 
years and over. 
3.3. Predictors of Poly Psychotropic Medication 
Comparisons could also be drawn between children who were reported to have been 
prescribed two or more psychotropic medications (n = 295) with those prescribed a single 
medication (n = 486). A similar process was followed to identify the predictors among the 
child’s behaviors and the child and family characteristics. The resulting model was 
significant and consisted of one function (canonical correlation 0.256; Wilk’s Lambda 
0.934: chi sq 52.8: df 7; p < 0.001). Table 4 summarizes the structure matrix of the variables 
that contributed significantly to the discriminant function. These showed a different 
pattern to the previous analysis. 
Table 4. The structure matrix of variables that best discriminated between children receiving poly psychotropic 
medication and the percentages within the subgroupings of the predictor variable. 
Variables Loading % Poly Psychotropic Medication 
Age group of child  0.668 2–5 yrs (23.4%), 6–7 yrs (38.0%), 8+ yrs (46.7%) 
Age of onset 0.414 
Under 12 months (50%), 12–23 months (33.1%), 24–35 months (34.7%), 36–47 
months (41.75), 48+ months (25.0%) 
Gender  0.344 Male (39.7%), female (28.4%) 
Aimless pacing  −0.312 Paces (29.3%), no pacing (39.7%)  
Type of disability 0.301 ASD Levels 2 and 3 (31.8%), ASD Level 1 (36.1%), ID (44.7%) 
The use of polypharmacy treatment is most associated with children aged eight and 
over and with those whose disability was evident either in the first 12 months (such as 
those with an intellectual disability) or at three to four years of age (when ASDs become 
more apparent). In addition, males rather than females and those children who did not 
pace aimlessly were more likely to receive two or more medications as were persons with 
intellectual disabilities rather than those with ASD. 
4. Discussion 
Psychotropic medication is used in sizable numbers of Iranian children with 
intellectual disabilities and even more in those who have ASD. Although direct 
comparison with rates in other countries must be conducted cautiously because of 
sampling differences, these data suggest that they exceed those reported in the USA and 
Europe as noted in the Introduction and is a point to which we will return below. 
The data also provide an insight into the differences between the children prescribed 
medications and those who were not, foremost of which was the child’s disability. This 
was more likely to occur in children who had a diagnosis of ASD, and this effect was 
present even when the behavioral characteristics were taken into account statistically. 
However, certain behaviors did add to the likelihood of psychotropic medications being 
prescribed, notably: hyperactivity, aimless pacing, and wandering, all of which can cause 
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stress in families, especially those living in crowded apartments and houses. Yet in this 
sample, a father’s education—but not mother’s—added more to the discriminant function 
than did the behavioral indicators, in that children of fathers with higher levels of 
education were less likely to receive psychotropic medication. Assuming that these 
parents had higher incomes, factors other than the cost associated with purchasing 
medications need to be considered. Among the possibilities would be greater use of 
private therapies and pre-school education that families obtained through access to 
information such as books and the Internet. These advantages of more affluent families 
are well attested in Western countries [22]. 
The data also confirmed the reports in the international literature that males and 
older children were more likely to receive medications, although in this study, they made 
less of a contribution to the discriminative function than the variables noted above. 
However, one particular concern is the high proportion of children under six years of age 
receiving medication when this is discouraged internationally, not least because these 
drugs are not licensed for use with such young children [8]. 
Around one quarter of all children received two or more psychotropic medications, 
a figure that is similar to that reported from other studies. The discriminant analysis 
comparing single and multiple usage identified a different set of predictors, chief of which 
were the age of the child combined with the age of onset of the child’s condition. This 
suggests that the longer the child’s condition persists, the greater the likelihood that more 
than one medication will be prescribed. Other predictors were also identified, namely the 
increased likelihood with males and when pacing behaviors were not present, along with 
increased multiple use among children with intellectual disabilities. The latter finding is 
novel as comparative data had not featured in past research. 
The number of children reported to have seizures was lower than that reported in 
Western studies [23,24] with just over one quarter in receipt of anti-convulsant 
medication. The lack of experienced diagnosticians is likely to be a major factor. 
The study has a number of limitations. No information was gathered on the reasons 
for why the children had been prescribed the medications and the period of time the 
children had been taking them. Details of changes in the children’s behavior and of any 
side effects were not requested. It was also a cross-sectional study whereas longitudinal 
data on usage and changes in children would be valuable and especially necessary in Iran 
given the high usage of psychotropic medication revealed by these data. A wider age 
range might also be considered as international studies suggest higher rates of prescribing 
among teenagers. In addition, the present study excluded children with more severe 
intellectual disabilities and/or ASD who attended centers run by the Iranian Social 
Welfare Organization as they were deemed ineligible to attend schools. Hence, these data 
may underestimate the use of psychotropic medications within these populations. 
The central message to emerge from this study is the likely overuse of psychotropic 
medication with young children in Iran compared to Western countries [2,3]. A similar 
pattern of overuse has been reported for the use of antibiotics in the general Iranian 
population as well as for other medical procedures [25]. However, a reliance on 
pharmacology by parents and doctors often results from inadequate or non-existent 
alternatives [26]. This is compounded in Iran by a lack of specialist medical expertise and 
a reliance on privately funded general physicians [16]. Internationally, there is 
widespread agreement as to the need for multi-disciplinary assessments involving 
psychologists, therapists, and educators as well as the use of behavioral, therapeutic, and 
educational interventions to nurture children’s development and support families in their 
care [4,11,27]. Medication may play a short-term supportive role within such 
interventions, but it should not be the central or sole form of intervention. A priority 
would be to extend the availability of these multi-disciplinary services across Iran and 
especially in the early years [28]. These would not only produce a better quality of life for 
children and families but also lead to more effective health and social care services within 
the country. 
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5. Conclusions 
High proportions of Iranian children with ASD and ID receive psychotropic 
medication, including children aged five and under. This is despite the known side effects 
of using these medications, some of which are not licensed for use in children. The rates 
are higher in children who have ASD and those showing difficult-to-manage behaviors 
such as hyperactivity, but less so for children of fathers with higher levels of education. 
The lack of alternative interventions may be a significant driver for the use of psychotropic 
medications, but these do not address the developmental needs of the children. Rather, 
multi-disciplinary, behavioral, therapeutic, and educational interventions are required, 
but these are not available widely in Iran, although a start has been made. 
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